ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Micropartical-Associated Thrombin Generation in Patients with Philadelphia-Negative Myeloproliferative Neoplasms

O. Matvienko, N. Silina, N. Korsakova, E. Efremova, M. Fominyh, L. Papayan, O. Golovina, V. Shuvaev, S. Voloshin

Russian Research Institute of Hematology and Transfusiology, Saint Petersburg, Russian Federation

Abstract Number: PB0364

Meeting: ISTH 2020 Congress

Theme: Coagulation and Natural Anticoagulants » Microparticles

Background: Essential Thrombocythemia (ET) and Polycythemia Vera (PV) are Philadelphia-negative myeloproliferative neoplasms (MPN). PV and ET have some common properties such as relatively normal maturation of cells and similarity of clinical symptoms. As known, MPN patients have a high risk of thrombotic complications. Activation and damage of blood cells in patients with ET and PV can lead to microparticles (MP) release. MP expresses tissue factor (TF) and procoagulant phospholipids on their surface that can enhance prothrombogenic potential of blood plasma.

Aims: Estimation of MP significance for thrombin generation in the group of patients with ET and PV.

Methods: The study included 64 MPN patients (25 – 76 years, median = 40) with ET and PV which were combined in one group because of the similarity of pathogenesis. Reference blood samples were obtained from 30 healthy people. Thrombin generation was measured in platelet-free plasma with Calibrated Automated Thrombinography (CAT). Following reagents were used: «FluCa‑kit», «PRP-reagent», containing rTF (1pM), «MP-reagent», containing negatively charged phospholipids (4µM), with CTI (40 µ/ml). Endogenous thrombin potential (ETP, nM*min) and peak thrombin (Peak, nM) were evaluated.
Data were described by non-parametric methods using the median (Me), 95% confidence interval (CI) and Mann-Whitney U test (Statistica 12.0). P< 0,05 was considered significant.

Results: Parameters of CAT are presented in table.* – p< 0,05, ** - p< 0,0001 for difference with controls
«PRP-reagent» and «MP-Reagent» allow to estimate thrombin generation which depends on procoagulant phospholipids and TF, respectively. Significant differences were found when were used both of that reagents but using «MP-Reagent» allowed to give more considerable differences.

Conclusions: MP enhance thrombin generation and increase prothrombogenic potential of patients with MPN due to TF and procoagulant phospholipids expressed on their surfaces. MP carrying TF have more significance for hypercoagulability.

Parameters «PRP-Reagent» Patients (N=64) «PRP-Reagent» Controls (N=30) «MP-Reagent» Patients (N=64) «MP-Reagent» Controls (N=24)
ETP (nM·min) 570,9* (128,0-1470,0) 471,8 (265,0-610,0) 798,0* (123,0-2366,0) 566,5 (57,2-1024,3)
Peak(nМ) 17,7 (3,9-93,0) 18,4 (8,8-28,6) 72,0** (7,1-107,0) 46,3 (20,2-93,2)

[Thrombogram parameters in the group of patients and control group (Me, 95% CI).]

To cite this abstract in AMA style:

Matvienko O, Silina N, Korsakova N, Efremova E, Fominyh M, Papayan L, Golovina O, Shuvaev V, Voloshin S. Micropartical-Associated Thrombin Generation in Patients with Philadelphia-Negative Myeloproliferative Neoplasms [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/micropartical-associated-thrombin-generation-in-patients-with-philadelphia-negative-myeloproliferative-neoplasms/. Accessed August 15, 2022.

« Back to ISTH 2020 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/micropartical-associated-thrombin-generation-in-patients-with-philadelphia-negative-myeloproliferative-neoplasms/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley